ID
24607
Description
Study ID: 100470 Clinical Study ID: SCO100470 Study Title: A multicentre, randomised, double-blind, parallel group, 24 week study to compare the effect of salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via DISKUS®/ACCUHALER® inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone propionate/salmeterol Trade Name: Serevent Study Indication: Pulmonary Disease, Chronic Obstructive
Keywords
Versions (3)
- 8/6/17 8/6/17 -
- 8/8/17 8/8/17 -
- 8/8/17 8/8/17 -
Uploaded on
August 8, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
concomitant medication salmeterol/fluticasone propionate combination compared to salmeterol on COPD 100470
concomitant medication salmeterol/fluticasone propionate combination compared to salmeterol on COPD 100470
Description
COPD CONCOMITANT MEDICATIONS
Alias
- UMLS CUI-1
- C2347852
- UMLS CUI-2
- C0024117
Description
If "yes" to COPD concomitant medication, record each medication separately by fulfilling the following items.
Alias
- UMLS CUI-1
- C2347852
- UMLS CUI-2
- C0024117
Description
Trade name preferred.
Data type
text
Alias
- UMLS CUI [1]
- C2360065
Description
unit dose
Data type
integer
Alias
- UMLS CUI [1]
- C0869039
Description
units of medication
Data type
text
Alias
- UMLS CUI [1]
- C1519795
Description
frequency of medication
Data type
text
Alias
- UMLS CUI [1]
- C3476109
Description
medication routes
Data type
text
Alias
- UMLS CUI [1]
- C0013153
Description
start date of medication
Data type
date
Alias
- UMLS CUI [1,1]
- C0013227
- UMLS CUI [1,2]
- C0808070
Description
medication taken prior to study
Data type
text
Alias
- UMLS CUI [1]
- C2826667
Description
stop date of medication
Data type
date
Alias
- UMLS CUI [1,1]
- C0013227
- UMLS CUI [1,2]
- C0806020
Description
concomitant medication ongoing
Data type
text
Alias
- UMLS CUI [1]
- C2826666
Description
drug adminstered for a COPD exacerbation
Data type
text
Alias
- UMLS CUI [1,1]
- C3469597
- UMLS CUI [1,2]
- C0740304
Description
NON-COPD CONCOMITANT MEDICATIONS
Alias
- UMLS CUI-1
- C2347852
Description
If "yes" to non-COPD concomitant medication, record each medication separately by fulfilling the following items.
Alias
- UMLS CUI-1
- C2347852
Description
Trade name preferred.
Data type
text
Alias
- UMLS CUI [1]
- C2360065
Description
unit dose
Data type
integer
Alias
- UMLS CUI [1]
- C0869039
Description
units of medication
Data type
text
Alias
- UMLS CUI [1]
- C1519795
Description
frequency of medication
Data type
text
Alias
- UMLS CUI [1]
- C3476109
Description
medication routes
Data type
text
Alias
- UMLS CUI [1]
- C0013153
Description
reason for medication
Data type
text
Alias
- UMLS CUI [1,1]
- C0392360
- UMLS CUI [1,2]
- C0013227
Description
start date of medication
Data type
date
Alias
- UMLS CUI [1,1]
- C0013227
- UMLS CUI [1,2]
- C0808070
Description
medication taken prior to study
Data type
text
Alias
- UMLS CUI [1]
- C2826667
Description
stop date of medication
Data type
date
Alias
- UMLS CUI [1,1]
- C0013227
- UMLS CUI [1,2]
- C0806020
Description
concomitant medication ongoing
Data type
text
Alias
- UMLS CUI [1]
- C2826666
Similar models
concomitant medication salmeterol/fluticasone propionate combination compared to salmeterol on COPD 100470
C0024117 (UMLS CUI-2)
C0024117 (UMLS CUI [1,2])
C0024117 (UMLS CUI-2)
C0808070 (UMLS CUI [1,2])
C0806020 (UMLS CUI [1,2])
C0740304 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,2])
C0808070 (UMLS CUI [1,2])
C0806020 (UMLS CUI [1,2])
No comments